90Yttrium-Ibritumomab-Tiuxetan as First-Line Treatment for Follicular Lymphoma: 30 Months of Follow-Up Data From an International Multicenter Phase II Clinical Trial.

CW Scholz; A Pinto; Werner Linkesch; O Lindén; A Viardot; U Keller; G Hess; S Lastoria; K Lerch; F Frigeri; M Arcamone; A Stroux; B Frericks; C Pott; A Pezzutto

doi:10.1200/JCO.2011.41.1553

90Yttrium-Ibritumomab-Tiuxetan as First-Line Treatment for Follicular Lymphoma: 30 Months of Follow-Up Data From an International Multicenter Phase II Clinical Trial.

CW Scholz
, A Pinto
, Werner Linkesch
, O Lindén
, A Viardot
, U Keller
, G Hess
, S Lastoria
, K Lerch
, F Frigeri
, M Arcamone
, A Stroux
, B Frericks
, C Pott
, A Pezzutto

Division of Haematology

Research output: Contribution to journal › Research article

76 Citations (Web of Science)

Original language	English
Journal	Journal of Clinical Oncology
DOIs	https://doi.org/10.1200/JCO.2011.41.1553
Publication status	Published - 2013

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Branches of science

302 Clinical Medicine

Research Fields

Cancer Research

DOI

10.1200/JCO.2011.41.1553

Links

Cite this

Scholz, CW., Pinto, A., Linkesch, W., Lindén, O., Viardot, A., Keller, U., Hess, G., Lastoria, S., Lerch, K., Frigeri, F., Arcamone, M., Stroux, A., Frericks, B., Pott, C., & Pezzutto, A. (2013). 90Yttrium-Ibritumomab-Tiuxetan as First-Line Treatment for Follicular Lymphoma: 30 Months of Follow-Up Data From an International Multicenter Phase II Clinical Trial. Journal of Clinical Oncology. https://doi.org/10.1200/JCO.2011.41.1553

@article{f84dc5e3f0df4f38b0f4f31b9b37b2e7,

title = "90Yttrium-Ibritumomab-Tiuxetan as First-Line Treatment for Follicular Lymphoma: 30 Months of Follow-Up Data From an International Multicenter Phase II Clinical Trial.",

author = "CW Scholz and A Pinto and Werner Linkesch and O Lind{\'e}n and A Viardot and U Keller and G Hess and S Lastoria and K Lerch and F Frigeri and M Arcamone and A Stroux and B Frericks and C Pott and A Pezzutto",

year = "2013",

doi = "10.1200/JCO.2011.41.1553",

language = "English",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "Lippincott Williams and Wilkins",

}

Scholz, CW, Pinto, A, Linkesch, W, Lindén, O, Viardot, A, Keller, U, Hess, G, Lastoria, S, Lerch, K, Frigeri, F, Arcamone, M, Stroux, A, Frericks, B, Pott, C & Pezzutto, A 2013, '90Yttrium-Ibritumomab-Tiuxetan as First-Line Treatment for Follicular Lymphoma: 30 Months of Follow-Up Data From an International Multicenter Phase II Clinical Trial.', Journal of Clinical Oncology. https://doi.org/10.1200/JCO.2011.41.1553

TY - JOUR

T1 - 90Yttrium-Ibritumomab-Tiuxetan as First-Line Treatment for Follicular Lymphoma: 30 Months of Follow-Up Data From an International Multicenter Phase II Clinical Trial.

AU - Scholz, CW

AU - Pinto, A

AU - Linkesch, Werner

AU - Lindén, O

AU - Viardot, A

AU - Keller, U

AU - Hess, G

AU - Lastoria, S

AU - Lerch, K

AU - Frigeri, F

AU - Arcamone, M

AU - Stroux, A

AU - Frericks, B

AU - Pott, C

AU - Pezzutto, A

PY - 2013

Y1 - 2013

UR - https://www.webofscience.com/wos/woscc/full-record/WOS:000313793700010

UR - https://pubmed.ncbi.nlm.nih.gov/23233718

U2 - 10.1200/JCO.2011.41.1553

DO - 10.1200/JCO.2011.41.1553

M3 - Research article

C2 - 23233718

SN - 0732-183X

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

ER -